Showing 4651-4660 of 5910 results for "".
- US Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry AMDhttps://modernod.com/news/us-phase-2-study-published-in-osli-retina-highlights-the-safety-and-efficacy-of-risuteganib-in-patients-with-dry-amd/2479429/Allegro Ophthalmics announced that the results of the company’s US phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina. Entitled
- Oculus Supports IMI in Raising Myopia Awarenesshttps://modernod.com/news/oculus-supports-imi-in-raising-myopia-awareness/2479430/Oculus has joined the International Myopia Institute (IMI) in tackling myopia awareness and will support the IMI activities to advance the research of myopia to prevent future vision impairment and blindness. “We are delighted about the cooperation. Our mission at Oculus is to support eye
- RxSight Announces Pricing of Initial Public Offeringhttps://modernod.com/news/rxsight-announces-pricing-of-initial-public-offering/2479423/RxSight announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16 per share. The gross proceeds to RxSight from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and
- Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura Ahead of Schedulehttps://modernod.com/news/iveric-bio-completes-patient-enrollment-of-gather2-pivotal-clinical-trial-of-zimura-ahead-of-schedule-2/2479422/Iveric bio announced the early completion of patient enrollment of GATHER2, the company’s second pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company expects topline GATHE
- Ocular Therapeutix Announces First Patient Dosed in US-Based Phase 1 Trial of OTX-TKI for Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-us-based-phase-1-clinical-trial-of-otx-tki-for-the-treatment-of-wet-amd/2479421/Ocular Therapeutix announced that it has dosed the first patient in the United States phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration (AMD). “We are very excited to have recently begu
- FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet AMD and DMEhttps://modernod.com/news/fda-accepts-application-for-genentechs-faricimab-for-the-treatment-of-wet-amd-and-dme/2479419/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic r
- Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura Ahead of Schedulehttps://modernod.com/news/iveric-bio-completes-patient-enrollment-of-gather2-pivotal-clinical-trial-of-zimura-ahead-of-schedule/2479414/Iveric bio announced the early completion of patient enrollment of GATHER2, the company’s second pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company expects topline GATHE
- Allegro Announces Positive Results of Vehicle-Controlled Ex-US Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-US vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, MD, at the 2021 American Society of Cataract and Refractive S
- BVI Announces Collaboration With BeyeOnics Visionhttps://modernod.com/news/bvi-announces-collaboration-with-beyeonics-vision/2479411/BVI announces a collaboration with Israel-based BeyeOnics Vision, a maker of in head-mounted display, digital data, and imaging processing. BeyeOnics Vision has been developing BeyeOnics 1, which the company describes as the first and only ophthalmic digital imaging system replacing the op
- LumiThera: Data Show Valeda Treatments Improve Vision and Retinal Function in Dry AMD patientshttps://modernod.com/news/lumithera-data-show-valeda-treatments-improve-vision-and-retinal-function-in-dry-amd-patients/2479408/LumiThera, a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, announced the final topline data from the ELECTROLIGHT pilot study in intermediate dry AMD patients. A total of 23 eyes from 15 subjects with dry AMD were enro